Devita, Hellman, and Rosenberg's Cancer

LWBK1006-23 LWW-Govindan-Review December 12, 2011 19:10

314 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

responding to platinum-based combination therapy and should usually

be offered chemotherapy. Secondary debulking surgery may also be of

benefit. Hormonal therapy in ovarian cancer generally produces response

rates of only 10% to 15% and is usually reserved for patients who can-

not tolerate other therapy. It has also been recommended as the initial

salvage therapy in patients who have an increasing CA-125 as their only

manifestation of recurrent disease.

Answer 23.1.17. The answer is C.

Clear cell histology is commonly associated with hypercalcemia. The

other statements are true.

Answer 23.1.18. The answer is B.

Current evidence does not support maintenance chemotherapy with

paclitaxel or topotecan after adjuvant chemotherapy for patients with

advanced disease. The role of maintenance bevacizumab is being investi-

gated in ongoing clinical trials.

SECTION 2 NONOVARIAN

MATTHEW A. POWELL

DIRECTIONS Each of the numbered items below is followed by lettered answers. Select the

ONE lettered answer that is BEST in each case unless instructed otherwise.

QUESTIONS

Question 23.2.1. Type I endometrial cancers have all the following features, EXCEPT:

A. Most of these cancers have serous or clear cell histology.

B. Type I endometrial cancers account for 80% of endometrial cancers.

C. They appear to arise via a progression pathway.

D. The precursor lesion is atypical hyperplasia.

Question 23.2.2. Type II endometrial cancers have which of the following features?

A. The precursor lesion is atypical hyperplasia.

B. The majority of tumors are slow-growing.

C. These cancers are unrelated to estrogen exposure.

D. All of the above.

Corresponding Chapters inCancer: Principles & Practice of Oncology,Ninth Edition: 100 (Molecular Biology

of Gynecologic Cancers), 101 (Cancer of the Cervix, Vagina, and Vulva), 102 (Cancers of the Uterine Body) and

103 (Gestational Trophoblastic Neoplasms).